ADAR1: A New Target for Immuno-oncology Therapy

Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target. Three recent studies...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cell 2019-03, Vol.73 (5), p.866-868
Hauptverfasser:	Bhate, Amruta, Sun, Tao, Li, Jin Billy
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Deaminase - genetics Adenosine Deaminase - immunology Adenosine Deaminase - metabolism Animals Cell Survival CRISPR-Cas Systems Gene Editing Gene Expression Regulation, Enzymologic Gene Expression Regulation, Neoplastic Genetic Therapy - methods Humans Immunity, Innate Immunotherapy - methods Interferon-Induced Helicase, IFIH1 - genetics Interferon-Induced Helicase, IFIH1 - metabolism Neoplasms - enzymology Neoplasms - genetics Neoplasms - immunology Neoplasms - therapy RNA Editing RNA, Double-Stranded - genetics RNA, Double-Stranded - immunology RNA, Double-Stranded - metabolism RNA-Binding Proteins - genetics RNA-Binding Proteins - immunology RNA-Binding Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target. Three recent studies by Ishizuka et al. (2019), Liu et al. (2019), and Gannon et al. (2018) show that deleting RNA editing enzyme ADAR1 could induce higher cell lethality and render tumor cells more vulnerable to immunotherapy, pinpointing ADAR1 as a new immuno-oncology target.
ISSN:	1097-2765 1097-4164
DOI:	10.1016/j.molcel.2019.02.021